Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT00966693Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2009
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and thalidomide in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate (CR + VGPR + PR). Started Aug 2009; status: completed.
02
Drugs
lenalidomidethalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00966693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00966693.